<?xml version="1.0" encoding="ISO-8859-1"?><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
<front>
<journal-meta>
<journal-id>1029-3043</journal-id>
<journal-title><![CDATA[Medicentro Electrónica]]></journal-title>
<abbrev-journal-title><![CDATA[Medicentro Electrónica]]></abbrev-journal-title>
<issn>1029-3043</issn>
<publisher>
<publisher-name><![CDATA[Universidad de Ciencias Médicas de Villa Clara]]></publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id>S1029-30432024000100009</article-id>
<title-group>
<article-title xml:lang="es"><![CDATA[Cáncer de próstata: Un problema de salud en pacientes adultos]]></article-title>
<article-title xml:lang="en"><![CDATA[Prostate cancer: a health problem in adult patients]]></article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Cuellar López]]></surname>
<given-names><![CDATA[Dervisyan]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Caron Girón]]></surname>
<given-names><![CDATA[Jenisfer]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[González Carmona]]></surname>
<given-names><![CDATA[Esther Gilda]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
</contrib-group>
<aff id="Af1">
<institution><![CDATA[,Hospital Universitario Clínico-Quirúrgico «Arnaldo Milián Castro»  ]]></institution>
<addr-line><![CDATA[Santa Clara Villa Clara]]></addr-line>
<country>Cuba</country>
</aff>
<pub-date pub-type="pub">
<day>00</day>
<month>00</month>
<year>2024</year>
</pub-date>
<pub-date pub-type="epub">
<day>00</day>
<month>00</month>
<year>2024</year>
</pub-date>
<volume>28</volume>
<copyright-statement/>
<copyright-year/>
<self-uri xlink:href="http://scielo.sld.cu/scielo.php?script=sci_arttext&amp;pid=S1029-30432024000100009&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://scielo.sld.cu/scielo.php?script=sci_abstract&amp;pid=S1029-30432024000100009&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://scielo.sld.cu/scielo.php?script=sci_pdf&amp;pid=S1029-30432024000100009&amp;lng=en&amp;nrm=iso"></self-uri><abstract abstract-type="short" xml:lang="es"><p><![CDATA[RESUMEN  Introducción:  Las enfermedades prostáticas, benignas y malignas, presentan una alta prevalencia a nivel mundial. Se estima que el 70 % de los hombres mayores de 50 años padece de síntomas obstructivos urinarios.  Objetivo: Describir los factores de riesgos del cáncer prostático en pacientes adultos.  Métodos: Se realizó estudio observacional, analítico retrospectivo en el Policlínico Juan Conteras en el período comprendido de enero 2022 a diciembre 2022. La población fue conformada por 212 pacientes masculinos que presentaban riesgo de presentar cáncer de próstata. Se empleó el análisis documental de las historias clínicas individuales y se presentó el odds ratio como medida de asociación con intervalo de confianza del 95 % y valor P.  Resultados:  Se estudiaron 212 pacientes con factores de riesgos del cáncer prostático: el 46,22 % no presentaron esta enfermedad y el 53,77 %, sí. La disuria OR=0,3306 (IC 95 % 0,1041-1,0496) P=0,0503. El alcoholismo OR=0,0583 (IC 95 % 0,0135-0,2514) P=0,0000. El tabaquismo OR=19,555 (IC 95% 9,7371-39,274) P=0,0000. El APF cáncer próstata OR=0,4605 (IC 95 % 0,2512-0,8442) P=0,0083. El nivel de PSA &gt;10 ng/ml OR= 429,57 (IC 95 % 56,635-3258,2) P=0.0000. Los factores protectores fueron: PSA &lt;4 ng/ml OR=0,0024 (IC 95 % 0,0005-0,0114) P= 0,0000 y el APP HPB OR=0,0065 (IC 95 % 0,0023-0,0184) P=0,0000.  Conclusiones:  El riesgo de padecer cáncer prostático afecta a pacientes del grupo de edad de 70 o más años, blancos, con APF cáncer de próstata y que consumen alcohol y tabaco. La sintomatología más frecuente fue la disuria. Los factores protectores fueron: el PSA &lt;4 ng/ml y APP HPB.]]></p></abstract>
<abstract abstract-type="short" xml:lang="en"><p><![CDATA[ABSTRACT  Introduction: benign and malignant prostate diseases have a high prevalence worldwide. It is estimated that 70% of men over 50 years of age suffer from urinary obstructive symptoms.  Objective: to describe the risk factors for prostate cancer in adult patients.  Methods: an observational, retrospective and analytical study was carried out at Juan Conteras Polyclinic from January 2022 to December 2022. The population was made up of 212 male patients who were at risk of developing prostate cancer. Document analysis of individual medical records was used and odds ratio was presented as a measure of association with a 95% confidence interval and P value.  Results: a number of 212 patients with risk factors for prostate cancer were studied: 46.22% of them did not have this disease and 53.77% did. Dysuria OR=0.3306 (95% CI, 0.1041-1.0496) P=0.0503. Alcoholism OR=0.0583 (95% CI, 0.0135-0.2514) P=0.0000. Smoking OR=19.555 (95% CI, 9.7371-39.274) P=0.0000. The APF prostate cancer OR=0.4605 (95% CI, 0.2512-0.8442) P=0.0083. The PSA level &gt;10 ng/ml, OR= 429.57 (95% CI, 56.635-3258.2) P=0.0000. The protective factors were PSA &lt;4 ng/ml, OR=0.0024 (95% CI, 0.0005-0.0114) P= 0.0000 and APP HPB OR=0.0065 (95% CI, 0.0023-0.0184) P=0.0000.  Conclusions: the risk of suffering from prostate cancer affects white patients aged 70 years or older with APF prostate cancer and alcohol and tobacco consumers. The most frequent symptom was dysuria. PSA &lt;4 ng/ml and APP HPB were the protective factors.]]></p></abstract>
<kwd-group>
<kwd lng="es"><![CDATA[neoplasia de la próstata]]></kwd>
<kwd lng="es"><![CDATA[factores de riesgo]]></kwd>
<kwd lng="es"><![CDATA[oportunidad relativa]]></kwd>
<kwd lng="en"><![CDATA[prostatic neoplasms]]></kwd>
<kwd lng="en"><![CDATA[risk factors]]></kwd>
<kwd lng="en"><![CDATA[odds ratio]]></kwd>
</kwd-group>
</article-meta>
</front><back>
<ref-list>
<ref id="B1">
<label>1</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Villegas-López]]></surname>
<given-names><![CDATA[OD]]></given-names>
</name>
<name>
<surname><![CDATA[Rubio-Espinoza]]></surname>
<given-names><![CDATA[MJ]]></given-names>
</name>
<name>
<surname><![CDATA[Martínez-Prieto]]></surname>
<given-names><![CDATA[GI]]></given-names>
</name>
<name>
<surname><![CDATA[Montes-del Real]]></surname>
<given-names><![CDATA[JA]]></given-names>
</name>
<name>
<surname><![CDATA[Ríos-González]]></surname>
<given-names><![CDATA[IR]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Nivel de conocimientos en la prevención del cáncer de próstata en derechohabientes de una unidad de medicina familiar]]></article-title>
<source><![CDATA[Rev Enferm Inst Mex Seguro Soc]]></source>
<year>2021</year>
<volume>29</volume>
<numero>1</numero>
<issue>1</issue>
</nlm-citation>
</ref>
<ref id="B2">
<label>2</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[García-Perdomo]]></surname>
<given-names><![CDATA[HA]]></given-names>
</name>
<name>
<surname><![CDATA[Zapata-Copete]]></surname>
<given-names><![CDATA[JA]]></given-names>
</name>
<name>
<surname><![CDATA[Sánchez]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Una mirada global y actualizada del cáncer de próstata]]></article-title>
<source><![CDATA[Rev Fac Med]]></source>
<year>2018</year>
<volume>66</volume>
<numero>3</numero>
<issue>3</issue>
</nlm-citation>
</ref>
<ref id="B3">
<label>3</label><nlm-citation citation-type="">
<collab>Cuba. Ministerio de Salud Pública</collab>
<source><![CDATA[Dirección Nacional de Registros Médicos y Estadísticas de salud. Anuario Estadístico de Salud 2020]]></source>
<year>2021</year>
</nlm-citation>
</ref>
<ref id="B4">
<label>4</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Islas Pérez]]></surname>
<given-names><![CDATA[LA]]></given-names>
</name>
<name>
<surname><![CDATA[Martínez Reséndiz]]></surname>
<given-names><![CDATA[JI]]></given-names>
</name>
<name>
<surname><![CDATA[Ruiz Hernández]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Ruvalcaba Ledezma]]></surname>
<given-names><![CDATA[JC]]></given-names>
</name>
<name>
<surname><![CDATA[Benítez Medina]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Beltrán Rodríguez]]></surname>
<given-names><![CDATA[MG]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Epidemiología del cáncer de próstata, sus determinantes y prevención]]></article-title>
<source><![CDATA[JONNPR]]></source>
<year>2020</year>
<volume>5</volume>
<numero>9</numero>
<issue>9</issue>
</nlm-citation>
</ref>
<ref id="B5">
<label>5</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Rendón]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Ullauri Torres]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Castillo León]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Romero Proaño]]></surname>
<given-names><![CDATA[SP]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Caracterización y evolución clínica de los pacientes con cáncer de próstata metastásico resistente a la castración atendidos en el servicio de urología de SOLCA (Guayaquil) 2013 a 2019]]></article-title>
<source><![CDATA[Rev Oncol Ecu]]></source>
<year>2021</year>
<volume>31</volume>
<numero>1</numero>
<issue>1</issue>
</nlm-citation>
</ref>
<ref id="B6">
<label>6</label><nlm-citation citation-type="book">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Auz Fierro]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Brito Chasiluisa]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
</person-group>
<source><![CDATA[Factores relacionados con la supervivencia de pacientes con cáncer de próstata en el hospital Solca núcleo de Quito durante el periodo 2003 - 2018.]]></source>
<year>2018</year>
<publisher-loc><![CDATA[Ecuador ]]></publisher-loc>
<publisher-name><![CDATA[Pontificia Universidad Católica del Ecuador]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B7">
<label>7</label><nlm-citation citation-type="">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Thomsen]]></surname>
<given-names><![CDATA[FB]]></given-names>
</name>
<name>
<surname><![CDATA[Westerberg]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Garmo]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
<name>
<surname><![CDATA[Robinson]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Holmberg]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Ulmert]]></surname>
<given-names><![CDATA[HD]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Prediction of metastatic prostate cancer by prostate-specific antigen in combination with T stage and Gleason Grade: Nationwide, population-based register study]]></article-title>
<source><![CDATA[PLoS One]]></source>
<year>2020</year>
<volume>15</volume>
<numero>1</numero>
<issue>1</issue>
</nlm-citation>
</ref>
<ref id="B8">
<label>8</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Barber]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Gerke]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
<name>
<surname><![CDATA[Markt]]></surname>
<given-names><![CDATA[SC]]></given-names>
</name>
<name>
<surname><![CDATA[Peisch]]></surname>
<given-names><![CDATA[SF]]></given-names>
</name>
<name>
<surname><![CDATA[Wilson]]></surname>
<given-names><![CDATA[KM]]></given-names>
</name>
<name>
<surname><![CDATA[Ahearn]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Family history of breast or prostate cancer and prostate cancer risk]]></article-title>
<source><![CDATA[Clin Cancer Res]]></source>
<year>2018</year>
<volume>24</volume>
<numero>23</numero>
<issue>23</issue>
</nlm-citation>
</ref>
<ref id="B9">
<label>9</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Birtle]]></surname>
<given-names><![CDATA[AJ]]></given-names>
</name>
<name>
<surname><![CDATA[Freeman]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Masters]]></surname>
<given-names><![CDATA[JRW]]></given-names>
</name>
<name>
<surname><![CDATA[Payne]]></surname>
<given-names><![CDATA[HA]]></given-names>
</name>
<name>
<surname><![CDATA[Harland]]></surname>
<given-names><![CDATA[SJ]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Clinical features of patients who present with metastatic prostate carcinoma and serum prostatespecific antigen (PSA) levels &amp;lt; 10 ng/mL the "PSA negative" patients]]></article-title>
<source><![CDATA[Cancer]]></source>
<year>2003</year>
<volume>98</volume>
<numero>11</numero>
<issue>11</issue>
<page-range>2362-7</page-range></nlm-citation>
</ref>
<ref id="B10">
<label>10</label><nlm-citation citation-type="book">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Orellana]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Cordero]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Duque]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
</person-group>
<source><![CDATA[Estudio Clínico y Epidemiológico de Cáncer de Próstata en el Hospital de Especialidades José Carrasco Arteaga de Cuenca - Ecuador, 2010-2015]]></source>
<year>2018</year>
<publisher-loc><![CDATA[Ecuador ]]></publisher-loc>
<publisher-name><![CDATA[Universidad del Azuay]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B11">
<label>11</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Martínez-González]]></surname>
<given-names><![CDATA[O]]></given-names>
</name>
<name>
<surname><![CDATA[Aguilar-Lemes]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Arcia-García]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Aguilar]]></surname>
<given-names><![CDATA[Y]]></given-names>
</name>
<name>
<surname><![CDATA[Corría- Paneque]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Neoplasia de próstata en pacientes mayores de 50 años. Policlínico Guillermo Gonzáles Polanco. Guisa. Enero-abril 2017]]></article-title>
<source><![CDATA[MULTIMED]]></source>
<year>2019</year>
<volume>23</volume>
<numero>5</numero>
<issue>5</issue>
</nlm-citation>
</ref>
<ref id="B12">
<label>12</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Bravo]]></surname>
<given-names><![CDATA[LE]]></given-names>
</name>
<name>
<surname><![CDATA[Muñoz]]></surname>
<given-names><![CDATA[N]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Epidemiología del cáncer en Colombia]]></article-title>
<source><![CDATA[Colomb Med (Cali)]]></source>
<year>2018</year>
<volume>49</volume>
<numero>1</numero>
<issue>1</issue>
</nlm-citation>
</ref>
<ref id="B13">
<label>13</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Sánchez Sánchez]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
<name>
<surname><![CDATA[Cruz Sánchez]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Rivas Acuña]]></surname>
<given-names><![CDATA[V]]></given-names>
</name>
<name>
<surname><![CDATA[Pérez Chan]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Prevalencia de factores de riesgo y sintomatología prostática en indígenas de Tabasco]]></article-title>
<source><![CDATA[Rev Cuid]]></source>
<year>2021</year>
<volume>12</volume>
<numero>2</numero>
<issue>2</issue>
</nlm-citation>
</ref>
</ref-list>
</back>
</article>
